PURPOSE: Diffuse large B-cell lymphoma (DLBCL) heterogeneity has prompted investigations for new biomarkers that can accurately predict survival. A previously reported 6-gene model combined with the International Prognostic Index (IPI) could predict patients' outcome. However, even these predictors are not capable of unambiguously identifying outcome, suggesting that additional biomarkers might improve their predictive power. EXPERIMENTAL DESIGN: We studied expression of 11 microRNAs (miRNA) that had previously been reported to have variable expression in DLBCL tumors. We measured the expression of each miRNA by quantitative real-time PCR analyses in 176 samples from uniformly treated DLBCL patients and correlated the results to survival. ...
Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DL...
International audienceMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B...
Background First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal ...
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) heterogeneity has prompted investigations for new bio...
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 3...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. This complex dise...
Diffuse large B-cell lymphoma is an aggressive malignancy of large transformed B- lymphocytes. The d...
MicroRNA is a small non-coding RNA (sncRNA) involved in gene silencing and regulating post-transcrip...
Introduction: MicroRNAs (miRNAs), as a family of non-coding RNAs, have opened a new window in cancer...
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the ...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
<div><p>Prognosis of patients with colorectal cancer (CRC) is generally poor because of the lack of ...
Colorectal cancer (CRC) is one of the worlds leading causes of cancer-related deaths in both men and...
Introduction: Non-coding RNAs have opened a new window in cancer biology. MicroRNAs (miRNAs), as a f...
Objective: Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-rel...
Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DL...
International audienceMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B...
Background First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal ...
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) heterogeneity has prompted investigations for new bio...
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 3...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. This complex dise...
Diffuse large B-cell lymphoma is an aggressive malignancy of large transformed B- lymphocytes. The d...
MicroRNA is a small non-coding RNA (sncRNA) involved in gene silencing and regulating post-transcrip...
Introduction: MicroRNAs (miRNAs), as a family of non-coding RNAs, have opened a new window in cancer...
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the ...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
<div><p>Prognosis of patients with colorectal cancer (CRC) is generally poor because of the lack of ...
Colorectal cancer (CRC) is one of the worlds leading causes of cancer-related deaths in both men and...
Introduction: Non-coding RNAs have opened a new window in cancer biology. MicroRNAs (miRNAs), as a f...
Objective: Colorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-rel...
Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DL...
International audienceMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B...
Background First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal ...